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Abstract
 .Thrombospondin-1 TSP-1 is synthesized, secreted, and incorporated into the extracellular matrix by a variety of cells,
 .including the endothelial cells. Addition of angiotensin II AII significantly induced TSP-1 mRNA in rat heart-derived
endothelial cells. TSP-1 mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 5 h. The
induction was superinduced by cycloheximide and blocked by actinomycin D. Losartan, an AT1 receptor antagonist, could
 .abolish the induction of TSP-1 mRNA by AII. Phorbol 12-myristate 13-acetate TPA was found to enhance TSP-1 mRNA
level whereas a protein kinase C inhibitor, H7, was shown to block the induction. Immunoblot analysis revealed that TSP-1
was detectable in the medium 4 h after AII stimulation. Our results suggest that the upregulation of TSP-1 by AII represents
an important mechanism leading to perivascular fibrosis in the heart.
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1. Introduction
 .Thrombospondin TSP was first identified as a
thrombin-sensitive protein which was released upon
w xthe activation of human platelets 1 . It is a multimod-
ular glycoprotein made up of three identical chains
linked by disulfide bonds. TSP can adhere to many
matrix macromolecules including heparan sulfate pro-
teoglycans, fibronectin, laminin, and types I and V
collagens. It can also bind to plasma proteins such as
fibrinogen and plasminogen, calcium ions, and cell
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surface receptors. TSP has been implicated in a num-
ber of biological processes such as hemostasis, cell
adhesion, proliferation, differentiation, wound heal-
w xing, and angiogenesis 2–5 .
It is now recognized that TSP is comprised of a
family of related proteins, TSP-1 to TSP-5. TSP-1
and TSP-2 are both trimeric and similar in structure
w x3 . These two genes have different tissue distribution
and are expressed differently in the developing mouse
w x6 . TSP-3, TSP-4, and TSP-5 are all pentameric
w xmolecules 3 . They resemble one another in struc-
ture, but differ from TSP-1 and TSP-2.
TSP-1 was synthesized and secreted by a number
of cultured cells including fibroblasts, smooth muscle
cells, epithelial cells, macrophages and endothelial
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w xcells 7 . Several growth factors have been demon-
strated to induce the expression of TSP-1. For exam-
ple, serum and platelet-derived growth factor were
found to upregulate TSP-1 gene expression in smooth
w xmuscle cells 8,9 . Transforming growth factor-b1
w xcould induce TSP-1 mRNA in 3T3 cells 10 , smooth
w x w xmuscle cells 11 , and adrenocortical cells 12 . In
addition, basic fibroblast growth factor was shown to
w xstimulate TSP-1 mRNA and protein in 3T3 cells 13 .
Endothelial cells are found to secrete TSP-1 and
w xpossess TSP-1 receptors 14–16 . TSP-1 inhibits the
proliferation and modulates the motility of these cells
w x17–19 . Previously we demonstrated that AII in-
w xduced the gene expression of endothelin-1 20 , TGF-
w xb1 21 , and tissue inhibitor of metalloproteinases
 . w xTIMP-1 22 . These proteins are known to be di-
rectly or indirectly involved in the synthesis of extra-
cellular matrix. In this study we examined the effect
of AII on the modulation on another matrix protein
TSP-1 and found that AII is a strong inducer of
TSP-1.
2. Materials and methods
2.1. Cell culture and materials
 .Rat heart-derived endothelial cells RHE were
w xprovided by Diglio et al. 23 . Cells were cultured in
Dulbecco’s modified Eagle’s medium DMEM, Life
.Technologies containing 10% fetal bovine serum
 .FBS , 2 mM L-glutamine and 25 mgrml gentamycin
at 378C in a humidified atmosphere of 5% CO . Cells2
were serially subcultured by treatment with trypsin
 .0.05% trypsin in 0.5 mM Versene and were used
for experimentation between passages 12 and 25.
These cells exhibited typical ‘cobblestone’ morphol-
ogy devoid of any smooth muscle cells. H7 and
 .phorbol 12-myristate 13-acetate TPA were obtained
w32 xfrom Sigma Chemical Company. P dCTP was ob-
tained from ICN. ITS was purchased from Collabora-
 .tive Biomedical Bedford, MA, USA . Fetal bovine
serum was obtained from Biofluids. Human TSP-1
was purchased from Life Technologies. All other
reagents used were of the highest grade commercially
available.
2.2. Northern blot analysis
Cells were seeded into 100 mm dishes containing
DMEM and 10% FBS. Near confluent cells were
changed to serum-free DMEM supplemented with
ITS 1 mM insulin, 6.25 mgrml transferrin and 6.25
.ngrml selenous acid for 24 h before the addition of
test agents. After the designated time, total RNA was
extracted using the acid guanidinium thiocyanate-
w xphenol-CHCl extraction method 24 . Fifteen micro-3
grams of RNA were denatured and separated by
electrophoresis on 1% agarose gel containing 2.2 M
formaldehyde. Following transfer, the RNA was co-
valently bound to GeneScreen DuPont-New England
.Nuclear by UV-crosslinking. Hybridization and
washing conditions were carried out according to the
w xmethod of Church and Gilbert 25 . A human TSP-1
cDNA probe, a 1100 bp EcoRI insert in pGEM-2
w x26 , was provided by Dr Jack Lawler, Harvard Uni-
w32 xversity. The cDNA was labeled with P dCTP using
random primer synthesis. The blots were exposed to
XAR films with intensifying screens. The intensity of
the bands was quantitated by Digital Imaging System
 .Alpha Innotech Corp. . Experiments were repeated
at least three times and representative data were
shown.
2.3. Immunoblot analysis of TSP-1
Near confluent RHE cultures in 100 mm dishes
were incubated with serum-free DMEM supple-
mented with ITS. Cells were treated with or without
AII for designated times. Conditioned media were
collected in the presence of protease inhibitors 2
mgrml aprotinin, 2 mgrml leupeptin and 0.5 mM
.phenylmethylsulfonyl fluoride . Secreted proteins in
the conditioned medium were precipitated with qui-
nine sulfate-SDS according to the method of Werb et
w xal. 27 . The precipitates were resuspended in
Laemmli SDS gel sample buffer and electrophoresed
 .on 6% SDS-PAGE. Human TSP-1 2 mg was in-
cluded as standard. Immunoblots were carried out
 .with rabbit anti-bovine TSP-1 antibodies 1:500
kindly provided by Dr Daniel Walz, Wayne State
.University at room temperature for 1.5 h and then
with goat anti-rabbit IgG conjugated to alkaline phos-
 .phatase 1:10 000, Sigma Chemical Company for 1
h. Color reaction was performed with nitroblue tetra-
zolium and 5-bromo-4-chloro-3-indolyl phosphate.
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Fig. 1. Time course of TSP-1 mRNA induction in rat heart
endothelial cells by AII. Near confluent cultures were exposed to
 y7 .AII 10 M for the times indicated. Fifteen mg of total RNA
were hybridized with a cDNA probe for human TSP-1. Hy-
 .bridization patterns of cells treated with AII for 0 min lane 1 ;
 .  .  .  . 30 min lane 2 ; 1 h lane 3 ; 2 h lane 4 ; 3 h lane 5 ; 4 h lane
.  .6 ; 5 h lane 7 ; are shown.
3. Results
Steady-state levels of TSP-1 mRNA were deter-
mined in RHE cultures by Northern blot analysis.
Two specific transcripts of TSP-1, 6.0 kb and 4.5 kb
were observed. The basal level of TSP-1 mRNA was
low. The mRNA level increased rapidly upon the
addition of AII. Levels of TSP-1 mRNA were in-
 .creased 5-fold at 2 h Fig. 1, lane 4 and then
 .declined over 5 h lane 7 . As shown in Fig. 2, TSP-1
mRNA responded to AII in a dose-dependent man-
ner.
Fig. 2. Dose-dependent induction of TSP-1 mRNA by AII. Near
confluent cultures of rat heart endothelial cells were treated with
10y12 M to 10y6 M of AII for 2 h. Fifteen mg of total RNA was
hybridized with a cDNA probe for human TSP-1. Hybridization
 . y12patterns of control cells lane 1 ; cells treated with 10 M AII
 . y11  . y10  . y9lane 2 ; 10 M AII lane 3 ; 10 M AII lane 4 ; 10 M
 . y8  . y7  . y6AII lane 5 ; 10 M AII lane 6 ; 10 M AII lane 7 ; 10 M
 .AII lane 8 ; are shown.
The next series of experiments were performed to
examine the mechanism of TSP-1 mRNA induction.
Inhibitors of protein and RNA synthesis were in-
cluded singly or in combination with AII. Cyclohex-
 .imide alone induced TSP-1 mRNA Fig. 3, lane 3 .
 .In the presence of AII and cycloheximide lane 4 the
 .induction was higher than AII alone lane 2 , imply-
ing that the induction does not require de novo
protein synthesis. In the presence of actinomycin D,
 .the induction was abolished lane 6 , indicating that
de novo RNA synthesis is required.
Losartan, a specific antagonist for AT-1 receptors
w x28 was included to examine whether the effect of
AII was mediated by AT1 receptors. In the presence
of 1 mM losartan, the induction of TSP-1 mRNA
 .decreased drastically Fig. 4, lane 4 , suggesting that
the induction of TSP-1 mRNA might be mediated by
AT1 receptors. Involvement of AT2 receptors was
investigated by including PD 123319, an AT2 recep-
w xtor antagonist 29 . PD 123319 at a concentration of 1
mM did not abolish the induction of TSP-1 mRNA
 .lane 6 , suggesting that AT2 receptors are not in-
volved.
The promoter of the TSP-1 gene has been shown
w xto contain AP-1 sites 30 . We next investigated if
AII exerted its effect through a protein kinase C-de-
pendent pathway. H7, a protein kinase C inhibitor
w x31 , was included. In these experiments, cells were
pretreated with 1 mM H7 for 30 min prior to the
 . Fig. 3. Effect of cycloheximide CHX and actinomycin D Act
.D on the induction of TSP-1 mRNA by AII. Near confluent
cultures of rat heart endothelial cells were treated with AII for 2
 . h in the absence or presence of CHX 20 mgrml or Act D 1
.mgrml . Fifteen mg of total RNA was hybridized with a human
TSP-1 cDNA probe. Hybridization patterns of control cells lane
. y7  .  .1 ; cells treated with 10 M AII lane 2 ; CHX lane 3 ; AII and
 .  .  .CHX lane 4 ; Act D lane 5 ; AII and Act D lane 6 ; are shown.
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Fig. 4. Effect of AII receptor antagonists losartan and PD 123319
on the induction of TSP-1 mRNA. Total RNA was isolated from
rat heart endothelial cell cultures in the absence or presence of
the antagonist and AII. Hybridization patterns of control cells
 . y7  .lane 1 ; cells treated with 10 M AII lane 2 ; 1 mM losartan
 .  . lane 3 ; 1 mM losartan and AII lane 4 ; 1 mM PD 123319 lane
.  .5 ; 1 mM PD 123319 and AII lane 6 ; are shown.
addition of AII. H7 was able to block the induction of
 .TSP-1 mRNA Fig. 5A, lane 4 . Treatment of cells
 .with TPA 100 ngrml for 2 h was found to stimu-
 .late the TSP-1 mRNA level Fig. 5A, lane 2 . Our
results suggest that the effect of AII is mediated by a
protein kinase C-dependent pathway.
Fig. 5. Effect of protein kinase C inhibitor and activator on the
induction of TSP-1 mRNA by AII. Panel A: near confluent rat
heart endothelial cells were pretreated with a protein kinase C
inhibitor, H7, for 30 min before the addition of AII for 2 h.
 .Hybridization patterns of control cells lane 1 ; cells treated with
y7  .  .  .10 M AII lane 2 ; 1 mM H7 lane 3 ; AII and H7 lane 4 ; are
shown. Panel B: near confluent cells were treated with or without
 .TPA 100 ngrml for 2 h. Hybridization patterns of control cells
 .  .lane 1 and cells treated with TPA lane 2 , are shown.
Fig. 6. Appearance of TSP-1 in the conditioned medium. Near
confluent rat heart endothelial cells were treated with or without
AII for different times. Secreted proteins in the conditioned
medium were precipitated with quinine sulfate-SDS and sepa-
rated on 6% SDS-PAGE. Immunoblot was carried out with rabbit
anti-bovine TSP-1 antibodies as described in Section 2. The
 .immunostaining patterns of control cells lane 1 ; cells treated
 .  .  .  .with AII for 2 h lane 2 ; 4 h lane 3 ; 6 h lane 4 , 8 h lane 5 ,
 .  .and 12 h lane 6 ; are shown. Human TSP-1 2 mg was included
 .as standard lane 7 .
In order to examine if the increase of TSP-1
mRNA correlates well with the appearance of TSP-1
in the conditioned medium, immunoblot analysis was
carried out. The conditioned media of control and
AII-treated cells were precipitated by quinine-sulfate-
SDS. In the absence of AII, RHE cells secreted only
 .trace amount of TSP-1 Fig. 6, lane 1 . A band of Mr
170 000 appeared in the medium 2 h after the addi-
 .tion of AII lane 2 . The amount of TSP-1 increased
 .from 4 to 6 h lanes 3,4 and stayed about the same
 .after 8 to 12 h of AII treatment lanes 5,6 .
4. Discussion
The present study demonstrated that AII acts on rat
heart endothelial cells to induce TSP-1 mRNA in a
dose and time dependent manner. The induction is
mediated by AT1 receptors and involves a protein
kinase C-dependent pathway. In addition, the in-
crease of TSP-1 mRNA correlated well with the
release of TSP-1 into the conditioned medium.
Our data demonstrated that the induction of TSP-1
mRNA by AII could be mainly attributed to tran-
scriptional activation. Although the elements respon-
sible for this activation were not characterized in the
present study, the promoter of the TSP-1 gene has
w xbeen shown to contain AP-1 sites 30 . Whether the
effect of AII is mediated by the AP-1 elements in our
system is under investigation. It is interesting to note
that TSP-1 mRNA is ‘superinduced’ in the presence
of cycloheximide and AII. The level of TSP-1 mRNA
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in the presence of cycloheximide alone is higher than
the basal level. Cycloheximide might inhibit the syn-
thesis of either labile ribonucleases that are involved
 .in degrading TSP-1 mRNA or repressor protein s
involved in the regulation of TSP-1 gene expression
w x32 .
The effect of TSP-1 varies with different cell
types. For example, TSP-1 has been shown to be an
autocrine growth factor for smooth muscle cells. It
can augment the mitogenic effect of epidermal growth
w xfactor on these cells 33,34 . On the other hand,
TSP-1 inhibits the proliferation of endothelial cells
w x17,18 . The production of TSP-1 in AII-treated rat
heart endothelial cultures in the present study may
provide a mechanism for the homeostatic regulation
of proliferation in these cells.
We previously reported that AII induced TGF-b1
w xmRNA in rat heart endothelial cells 21 . Since TGF-
b1 has been demonstrated to induce TSP-1 in several
w xcell types 10–12 , a question arises as to whether the
increase of TSP-1 level observed in this study is a
result of the secondary effect of TGF-b1. Two lines
of evidence appear to negate this possibility. First,
the kinetics of induction of TSP-1 mRNA precedes
that of TGF-b1. Secondly, the released TGF-b1 was
w xfound to be in the latent form by bioassays 21 .
TSP-1 was shown to activate the latent TGF-b1 in
w xbovine aortic endothelial cells 35,36 . The sequence
responsible for the activation has been localized to
the unique amino acids 412–415 found between the
w xfirst and the second repeats of TSP-1 37 . In our
preliminary experiment, TGF-b1 in the medium could
be converted to the active form when exogenous
 .TSP-1 20 mgrml was added to rat heart endothelial
 .cells results not shown . In the present study, the
TSP-1 in the conditioned medium is probably too
dilute to activate the latent TGF-b1. However, high
TSP-1 concentration may be achievable in a localized
microenvironment in vivo.
It has been well documented that cardiac fibrosis
occurs in renin-angiotensin-dependent hypertension.
The pattern of fibrosis generally progresses in the
adventia of intramyocardial arteries and finally ex-
w xtends into the interstitial space 38 . In addition to
TSP-1, AII could induce endothelin-1, TGF-b1, and
 .tissue inhibitor of metalloproteinases-1 TIMP-1 in
w xrat heart endothelial cultures 20–22 . These proteins
could modulate collagen metabolism of adjacent
w xsmooth muscle cells or fibroblasts 39,40 . Hence, the
enhanced production of TSP-1, TGF-b1, and TIMP-1
in response to the rise of AII by heart endothelial
cells during the development of hypertension may be
the initiating events that lead to perivascular fibrosis
in renovascular hypertension.
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